Safety and Efficacy of Renin–Angiotensin–Aldosterone System Inhibitors in COVID-19 Population

INTRODUCTION: The safety of renin–angiotensin–aldosterone system inhibitors (RAASi) among COVID-19 patients has been controversial since the onset of the pandemic. METHODS: Digital databases were queried to study the safety of RAASi in COVID-19. The primary outcome of interest was mortality. The sec...

Descripción completa

Detalles Bibliográficos
Autores principales: Sattar, Yasar, Mukuntharaj, Pradeeksha, Zghouzi, Mohamed, Suleiman, Abdul-Rahman M., Attique, Hassan, Ullah, Waqas, Sana, Muhammad Khawar, Zaher, Nathan, Mehmood, Maham, Doshi, Rajkumar P., Panchal, Ankur, Mir, Tanveer, Nadeem, Muhammad, Ali, Omar E., Mohamed, Mohamad, Bagur, Rodrigo, Elgendy, Islam Y., Mamas, Mamas A., Alraies, M. Chadi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237039/
https://www.ncbi.nlm.nih.gov/pubmed/34181203
http://dx.doi.org/10.1007/s40292-021-00462-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8237039/
https://www.ncbi.nlm.nih.gov/pubmed/34181203
http://dx.doi.org/10.1007/s40292-021-00462-w

Ejemplares similares